Long‐term outcome after radiotherapy alone for lymphocyte‐predominant Hodgkin lymphoma
- 10 August 2005
- Vol. 104 (6), 1221-1229
- https://doi.org/10.1002/cncr.21303
Abstract
BACKGROUND The curative potential of radiotherapy (RT) alone as initial treatment for patients with Stage I–II lymphocyte‐predominant Hodgkin lymphoma (LPHL) has not been defined well. METHODS Two hundred two patients who were treated between 1969 and 1995 were evaluated in a retrospective, multicenter study. RESULTS Patient characteristics were as follows: The median age was 31 years, 75% of patients were male, 80% of patients had Ann Arbor Stage I disease, 1% of patients had bulky disease, 3% of patients had B symptoms, 1% of patients had extranodal involvement, and 80% of patients had supradiaphragmatic disease. The RT fields were a full mantle field in 52% of patients, less than a full mantle field in 24% of patients, an inverted‐Y field in 17% of patients, less than an inverted‐Y field in 3% of patients, and total lymph node irradiation in 3% of patients. The median dose was 36 Gray. The median follow‐up was 15 years. The overall survival (OS) rate at 15 years was 83%, and freedom from progression (FFP) was observed in 82% of patients, including 84% of patients with Stage I disease and 73% of patients with Stage II disease. No recurrent LPHL and only 1 patient with non‐Hodgkin lymphoma (NHL) were reported after 15 years. Adverse prognostic factors that were identified on multifactor analysis were as follows: for OS, age 45 years or older (P < 0.0005), the presence of B symptoms (P = 0.002), increasing number of sites (P = 0.015); for FFP, increasing number of sites (P = 0.002). No significant difference was found in FFP in a comparison of patients who received elective mediastinal RT with patients who did not receive mediastinal RT (P = 0.11). Causes of death at 15 years were LPHL in 3% of patients, NHL in 2% of patients, in‐field malignancy in 2% of patients, in‐field cardiac/respiratory in 4% of patients, and other in 6% of patients. CONCLUSIONS The current data suggested that RT potentially may be curative for patients with Stage I–II LPHL and raise the possibility that limited‐field RT may be used without loss of treatment efficacy. Involved‐field RT warrants further investigation for patients with early‐stage LPHL. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Lymphocyte-Predominant Hodgkin’s Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection—A Study of the French Society of Pediatric OncologyJournal of Clinical Oncology, 2003
- Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trialBlood, 2003
- Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study GroupBlood, 2003
- Hodgkin's Disease — Time for a ChangeThe New England Journal of Medicine, 1997
- Clonality in Nodular Lymphocyte-Predominant Hodgkin's DiseaseThe New England Journal of Medicine, 1997
- Origin of Nodular Lymphocyte-Predominant Hodgkin's Disease from a Clonal Expansion of Highly Mutated Germinal-Center B CellsThe New England Journal of Medicine, 1997
- A note on quantifying follow-up in studies of failure timeControlled Clinical Trials, 1996
- Radiotherapy for early infradiaphragmatic Hodgkin's disease: the Australasian experienceRadiotherapy and Oncology, 1996
- The follicular non-Hodgkin's Lymphomas—I. The possibility of cureEuropean Journal of Cancer, 1996
- Nodular and Diffuse Types of Lymphocyte Predominance Hodgkin's DiseaseThe New England Journal of Medicine, 1988